Part of the multidistrict lawsuit over EpiPen price gouging, which involves racketeering and antitrust claims against Mylan NV, was certified as a class action Thursday by a Kansas federal judge, who also declined to let other EpiPen buyers proceed collectively, reported Bloomberg.
EpiPen, an epinephrine auto-injector that treats potentially fatal allergic reactions, has been a poster child for drug price-gouging since an uproar in 2016 over its increase from $50 a shot to $300.
The sprawling consolidated suit includes parallel proposed class actions on behalf of patients, insurers, and plan sponsors like employers, as well as individual claims by competitors.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.